Gilead's twice-yearly shot cut HIV infections by 96% in trial
September 12, 2024 at 09:29 AM EDT
The data sets the stage for likely approval of Gilead's Lenacapavir for HIV prevention.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Home | News | Travel | Restaurants | Nightlife | Things To Do | Shopping | Calendar | Directory | Real Estate | Blog | More
|